ABBN.SW: $86.10 ▼ -2.46 (-2.78%)ASML.AS: $1,560.80 ▼ -95.00 (-5.74%)ENR.DE: $162.50 ▲ 0.00 (0.00%)GLEN.L: $537.30 ▲ 2.00 (0.37%)IFX.DE: $80.56 ▲ 0.00 (0.00%)NOKIA.HE: $12.11 ▲ 0.11 (0.92%)RIO.L: $7,280.00 ▲ 16.00 (0.22%)AMD: $519.85 ▼ -31.78 (-5.76%)INTC: $132.28 ▼ -8.66 (-6.14%)MU: $1,051.77 ▼ -159.61 (-13.18%)WDC: $670.75 ▼ -61.87 (-8.45%)AAPL: $294.30 ▼ -2.71 (-0.91%)AMZN: $234.11 ▲ 1.32 (0.57%)NVDA: $200.04 ▼ -8.61 (-4.13%)AMAT: $585.88 ▼ -54.30 (-8.48%)CIEN: $459.85 ▼ -0.48 (-0.10%)STX: $1,038.59 ▼ -55.45 (-5.07%)

Company Details

MediWound Ltd.

MDWD - NASDAQ

Identifiants & Marche

Ticker MDWD
ISIN IL0011316309
CIK 0001593984
Bourse NASDAQ
Devise USD

Classification

Secteur Healthcare
Industrie Biotechnology

Entreprise

Pays IL
Siege N/A
Fondee N/A
Site Web Lien

Description

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel and bio-therapeutic solutions for tissue repair and regeneration. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was founded in 2000 and is headquartered in Yavne, Israel.